Researchers performed a two-sample Mendelian randomization analysis to investigate the associations between genetically proxied suppression of PDE5, a recognized pharmacological target for erectile dysfunction, fertility, subjective wellness, and sexual behavior.
Adcomm says Intercept’s rare liver disease drug should not get full approval
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva by a 13-1 vote, concluding that confirmatory
September 14, 2024